Clinical and cost data used
| Cost estimates (2013/2014) | ||||||
|---|---|---|---|---|---|---|
| Intervention | RR; return of symptoms* | Time period (months) | UK £ | € (set 1) | € (set 2) | € (set 3) |
| PTA with bail-out bare metal stents | 1 | – | £3248 | €3898 | €3898 | €3898 |
| Bare metal stents | 0.7261 | 12 | £3848 | €4354 | €4498 | €4282 |
| Drug-eluting stents | 0.5216 | 60 | £4208 | €4678 | €5053 | €5038 |
| Drug-eluting balloons | 0.2739 | 18 | £4604 | €4848 | €4888 | €5360 |
| Biomimetic (BioMimics 3D) stent | 0.2711 | 24 | £3968 | €4618 | €4618 | €4618 |
All data are from Jens et al, with the exception of the biomimetic BioMimics 3D stent, which comes from the Mimics trial, and drug-eluting stents, which comes from the 5-year Zilver PTX results.
*Defined as the need for clinically driven target lesion revascularisation.
PTA, percutaneous transluminal balloon angioplasty; RR, relative risk.